Phase II Multicenter Trial of Peptide Vaccination Therapy Using Novel Cancer Testis Antigens for Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
The phase I vaccination study using peptides derived from TTK, LY6K, and IMP-3 for locally
advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) who had failed
for the standard therapy indicated that the vaccine treatment were well tolerated and
feasible, and that antigen-specific T cell responses were strongly induced by the
vaccination with some objective clinical responses. Thus, we are currently initiating the
randomized phase II clinical vaccination study for the same cohort with ESCC to evaluate the
survival benefit of the cancer vaccination.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Overall survival after the 1st vaccination
2 years
No
Koji Kono, MD.PhD
Principal Investigator
University of Yamanashi, First Deparment of Surgery
Japan: Ministry of Health, Labor and Welfare
YMU-02
NCT00995358
November 2008
October 2011
Name | Location |
---|